Every material Form 8-K Structure Therapeutics Inc. has filed with the SEC since May 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Structure Therapeutics reported topline results from a Phase 1/2a single-dose study of ACCG-2671, an oral amylin receptor agonist, and 72-week results from an open-label extension of its Phase 2b aleniglipron trial. The filing shows aleniglipron participants reached up to 16.2% body weight loss, while ACCG-2671 showed a half-life of about 6 days but dose-related nausea and vomiting at the 5 mg and 10 mg doses.
Aleniglipron 72-week open-label extension: up to 16.2% mean body weight loss at the 180 mg dose, with fewer than 5% of participants discontinuing due to treatment-emergent adverse events
ACCG-2671 single ascending dose study (31 healthy participants): terminal half-life of about 6 days; nausea in 4 of 5 at 5 mg and in 6 of 6 at 10 mg
ACCG-2671 multiple ascending dose portion has begun, with topline data expected in the first half of 2027
Phase 3 ACCOMPLISH program for aleniglipron is enrolling, with topline data expected in the second half of 2028
Structure Therapeutics reported second quarter 2026 results, with a net loss of $106.2 million, up from $61.7 million a year earlier, as research and development expenses rose to $100.1 million from $54.7 million. The company said it has begun dosing patients in its Phase 3 ACCOMPLISH program for aleniglipron and expects its $1.3 billion in cash and short-term investments to fund operations and key clinical milestones through 2028.
Q2 2026 net loss of $106.2 million vs. $61.7 million in Q2 2025; share-based compensation of $12.6 million included
R&D expenses of $100.1 million vs. $54.7 million; G&A expenses of $18.6 million vs. $15.7 million
Cash, cash equivalents and short-term investments of $1.3 billion at June 30, 2026, down from $1.5 billion at March 31, 2026
John Berrios appointed Chief Commercial Officer; first patients dosed in Phase 3 ACCOMPLISH-1 and -2 trials
Structure Therapeutics reported a first-quarter 2026 net loss of $76.0 million, up from $46.8 million a year earlier, as research and development and G&A costs rose. The company also amended its at-the-market share sale agreement and raised the offering amount by $150 million to up to $400 million, which could add shares outstanding for shareholders.
Q1 2026 net loss was $76.0 million, compared with $46.8 million in Q1 2025.
R&D expenses rose to $66.5 million from $42.9 million; G&A expenses rose to $22.9 million from $13.4 million.
Cash, cash equivalents and short-term investments were $1.5 billion at March 31, 2026, which the company expects to fund operations through the end of 2028.
On May 7, 2026, the at-the-market offering was increased by $150 million to an aggregate offering price of up to $400 million; previously, 3,040,000 shares had been sold for gross proceeds of about $58.5 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Structure Therapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →